Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?

[1]  I. Pavord,et al.  Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. , 2016, The Lancet. Respiratory medicine.

[2]  Baldur P Magnusson,et al.  The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. , 2016, Pulmonary pharmacology & therapeutics.

[3]  D. Price,et al.  Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study , 2016, Respiratory Research.

[4]  J. Singh,et al.  Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS) , 2016, Respiratory Research.

[5]  M. Silkey,et al.  Setipiprant, a selective CRTH2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[7]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[8]  Stacy L. Gelhaus,et al.  Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation. , 2013, The Journal of allergy and clinical immunology.

[9]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[10]  Dave Singh,et al.  Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 , 2012, European Respiratory Journal.

[11]  W. Busse,et al.  Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. , 2011, American journal of respiratory and critical care medicine.

[12]  Ruchong Chen,et al.  Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. , 2016, The Journal of allergy and clinical immunology.